New pre-clotting method for fibrin glue in a non-sealed graft used in an LVAD: the KYO method.

Division of Therapeutic Strategy for Heart Failure, Department of Cardio-Thoracic Surgery, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Journal of Artificial Organs (Impact Factor: 1.41). 09/2010; 13(3):174-7. DOI: 10.1007/s10047-010-0504-1
Source: PubMed

ABSTRACT Pre-clotting has been applied to a vascular prosthesis with high permeability (non-sealed graft). In this study, conventional pre-clotting methods were compared with our novel method, which keeps high-yield optimization of hemostasis, the KYO method. Fibrinogen solution (A) and thrombin solution (B) of fibrin glue (Beriplast P Combi-Set(®)) were applied to the graft (Cooly low-porosity woven graft) by five methods; Group 1: control, without fibrin glue; Group 2: spray method, spraying solutions A and B simultaneously; Group 3: rub method, rubbing solution A first, and then rubbing solution B on the graft; Group 4: rub-and-spray method, rubbing solution A on the graft, then spraying solutions A and B; Group 5: the KYO method, rubbing solution A into the graft with the finger, then rubbing solution B on the graft. Burst pressure, the point of saline solution leakage, was measured 10 times for each group. The grafts were microscopically examined using HE staining and electron microscopy. The average burst pressure was 12.6 ± 1.5 mmHg in Group 1, 27.1 ± 3.3 mmHg in Group 2, 22.4 ± 7.1 mmHg in Group 3, 41.0 ± 9.0 mmHg in Group 4, and 300 mmHg in Group 5. Saline solution did not leak through the graft at a pressure of 300 mmHg in Group 5. There were statistically significant differences among the groups. The relationship between fibrin glue and the graft was unclear in all groups by HE staining. Electron microscopic photographs showed a smooth surface and fibrin glue permeating the graft fibers in Group 5. The KYO method was better than the others in terms of resistance to pressure. It was a very simple method, and could thus come into widespread use.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Short- to mid-term extracorporeal ventricular assist devices (VADs) are recommended for critical cardiogenic shock patients. We have designed a preclinical, single-use MedTech Mag-Lev VAD for one-month extracorporeal use. The impeller-rotor of the pump was suspended by a two degree-of-freedom active magnetic bearing in a 300 μm fluid gap, where the computational fluid dynamics analysis predicted a secondary flow of about 400-500 ml/min at a pump speed of 1800-2200 rpm. Three eddy current sensors were employed to implement noise- and drift-free magnetic levitation. The pump components were injection molded using polycarbonate for smooth surfaces as well as improved reproducibility, followed by coating with a biocompatible 2-methacryloyl-oxyethyl phosphorylcholine polymer. Chronic animal experiments were performed in nine calves. Three of the nine calves were excluded from analysis for problems with the circuit. Five of the six (83.3%) completed the 60 day duration of the study, while one prematurely died of massive bleeding due to inflow port detachment. The pump did not stop due to magnetic-levitation malfunction. Neither pump thrombosis nor major organ infarction was observed at autopsy. In comparison to machined surfaces, the injection-molded pump surfaces were thrombus-free after 60 day implantation. This study demonstrates the feasibility of MedTech Mag-Lev VAD for 60 day circulatory support.
    ASAIO journal (American Society for Artificial Internal Organs: 1992) 01/2013; 59(3):246-52. · 1.39 Impact Factor


Available from
Jun 4, 2014